Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

키워드

참고문헌 (65)

1. Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS), 2011, pp.29, 2866~2874
2. 심효섭, "Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group", Journal of Pathology and Translational Medicine, 47(2), pp.100~106 (2013), 대한병리학회[DOI]
3. 김효진, "Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group", Journal of Pathology and Translational Medicine, 48(1), pp.1~9 (2014), 대한병리학회[DOI]
4. 심효섭, "Molecular Testing of Lung Cancers", Journal of Pathology and Translational Medicine, 51(3), pp.242~254 (2017), 대한병리학회[DOI]
5. 신동훈, "Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group", Journal of Pathology and Translational Medicine, 53(3), pp.153~158 (2019), 대한병리학회[DOI]
6. Lindeman NI, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors : guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology", Arch Pathol Lab Med, 142, pp.321~346 (2018)
7. Kalemkerian GP, "Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors : American Society of Clinical Oncology Endorsement of the College of American Pathologists", International Association for the Study of Lung Cancer, J Clin Oncol, pp.2018, 36[DOI]
8. "NCCN Clinical practice guidelines in oncology (NCCN Guidelines) for non-small cell lung cancer, version 8.2020" (2020)[URL]
9. Genova C, "Targeted therapy of oncogenic-driven advanced non-small cell lung cancer : recent advances and new perspectives", Expert Rev Respir Med, 14, pp.367~383 (2020)
10. Del Re M, "erbB in NSCLC as a molecular target: current evidences and future directions", ESMO Open, 5, pp.e000724~ (2020)
11. Yoon HY, "Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study", PLoS One, 15, pp.e0228925~ (2020)
12. 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회
13. 이상화, "Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey", Journal of Pathology and Translational Medicine, 49(6), pp.481~488 (2015), 대한병리학회[DOI]
14. Janne PA, "Challenges of detecting EGFR T790M in gefitinib", erlotinib-resistant tumours, 2008, pp.60(Suppl 2), S3~S9
15. Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
16. Farago AF, "Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion", JCO Precis Oncol., 2018, pp.PO.18.0003~ (2018)
17. Ghimessy A, "Current therapy of KRASmutant lung cancer", Cancer Metastasis Rev, 39, pp.1159~1177 (2020)
18. Pennell NA, "Biomarker testing for patients with advanced non-small cell lung cancer : real-world issues and tough choices", Am Soc Clin Oncol Educ Book, 39, pp.531~542 (2019)
19. Rolfo C, "Challenges and opportunities of cfDNA analysis implementation in clinical practice : perspective of the International Society of Liquid Biopsy(ISLB)", Crit Rev Oncol Hematol, 151, pp.102978~ (2020)
20. Tafe LJ, "Non-small cell lung cancer as a precision oncology paradigm : emerging targets and tumor mutational burden(TMB)", Adv Anat Pathol, 27, pp.3~10 (2020)
21. Marabelle A, "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol, 21, pp.1353~1365 (2020)
22. Uruga H, "ALK(D5F3)CDx : an immunohistochemistry assay to identify ALK-positive NSCLC patients", Pharmgenomics Pers Med, 11, pp.147~155 (2018)
23. Marchio C, "ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research", Ann Oncol, 30, pp.1417~1427 (2019)
24. 구보미, "Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)", Journal of Pathology and Translational Medicine, 52(3), pp.148~156 (2018), 대한병리학회[DOI]
25. Bruno R, "Next generation sequencing for gene fusion analysis in lung cancer : a literature review", Diagnostics(Basel), 10, pp.521~ (2020)
26. 김지훈, "Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests", Journal of Pathology and Translational Medicine, 51(3), pp.191~204 (2017), 대한병리학회[DOI]
27. 이승은, "Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer", Journal of Korean Medical Science, 31(8), pp.1224~1230 (2016), 대한의학회
28. Sun PL, "High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas", Cancer Cytopathol, 121, pp.311~319 (2013)
29. Asaka S, "Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients : comparison between cell pellets, cell blocks and matching tissue specimens", Oncol Lett, 15, pp.1469~1474 (2018)
30. Roy-Chowdhuri S, "Concurrent fine needle aspirations and core needle biopsies : a comparative study of substrates for next-generation sequencing in solid organ malignancies", Mod Pathol, 30, pp.499~508 (2017)
31. Shiau CJ, "Sample features associated with success rates in population-based EGFR mutation testing", J Thorac Oncol, 9, pp.947~956 (2014)
32. da Cunha Santos G, "A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma", J Clin Pathol, 69, pp.607~611 (2016)
33. Roy-Chowdhuri S, "Biomarker testing in lung carcinoma cytology specimens : a perspective from members of the Pulmonary Pathology Society", Arch Pathol Lab Med, 140, pp.1267~1272 (2016)
34. Lozano MD, "Cytology smears in the era of molecular biomarkers in non-small cell lung cancer : doing more with less", Arch Pathol Lab Med, 142, pp.291~298 (2018)
35. Jain D, "Molecular pathology of lung cancer cytology specimens : a concise review", Arch Pathol Lab Med, 142, pp.1127~1133 (2018)
36. da Cunha Santos G, "Cytological preparations for molecular analysis : a review of technical procedures, advantages and limitations for referring samples for testing", Cytopathology, 29, pp.125~132 (2018)
37. Auger M, "A practical guide for ancillary studies in pulmonary cytologic specimens", Cancer Cytopathol., 126(Suppl 8), pp.599~614 (2018)
38. Aisner DL, "The revised College of American Pathologists", International Association for the Study of Lung Cancer, Arch Pathol Lab Med, pp.2018, 142[DOI]
39. 장선희, "Current status and future perspectives of liquid biopsy in non-small cell lung cancer", Journal of Pathology and Translational Medicine, 54(3), pp.204~212 (2020), 대한병리학회[DOI]
40. Nosaki K, "Re-biopsy status among nonsmall cell lung cancer patients in Japan : a retrospective study", Lung Cancer, 101, pp.1~8 (2016)
41. Siravegna G, "Integrating liquid biopsies into the management of cancer", Nat Rev Clin Oncol, 14, pp.531~548 (2017)
42. Passiglia F, "The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC : a systematic review and meta-analysis", Sci Rep, 8, pp.13379~ (2018)
43. Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
44. Remon J, "Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA", Ann Oncol, 28, pp.784~790 (2017)
45. Aisner DL, "Do more with less : tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing : the University of Colorado Experience", Arch Pathol Lab Med, 140, pp.1206~1220 (2016)
46. "Cobas EGFR mutation test v2" (2020)[URL]
47. Lim C, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario", Curr Oncol, 24, pp.103~110 (2017)
48. Anand K, "Clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma", Clin Lung Cancer, 21, pp.437~442 (2020)
49. Cheema PK, "Impact of reflex EGFR", ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer, 2017, pp.13, e130~e138
50. Indini A, "Novel treatment strategies for early-stage lung cancer : the oncologist's perspective", J Thorac Dis, 12, pp.3390~3398 (2020)
51. Wu YL, "Osimertinib in resected EGFR-mutated non-small-cell lung cancer", N Engl J Med, 383, pp.1711~1723 (2020)
52. Pelosi G, "DeltaNp63(p40)and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer : a novel two-hit, sparingmaterial approach", J Thorac Oncol, 7, pp.281~290 (2012)
53. Bass BP, "A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded(FFPE)tissue : how well do you know your FFPE specimen?", Arch Pathol Lab Med, 138, pp.1520~1530 (2014)
54. Compton CC, "Preanalytics and precision pathology : pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine", Arch Pathol Lab Med, 143, pp.1346~1363 (2019)
55. Dejmek A, "Preparation of DNA from cytological material : effects of fixation, staining, and mounting medium on DNA yield and quality", Cancer Cytopathol, 121, pp.344~353 (2013)
56. Miquelestorena-Standley E, "Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples", Mod Pathol, 33, pp.1505~1517 (2020)
57. 최성은, "Proposal of an Appropriate Decalcification Method of Bone Marrow Biopsy Specimens in the Era of Expanding Genetic Molecular Study", Journal of Pathology and Translational Medicine, 49(3), pp.236~242 (2015), 대한병리학회[DOI]
58. "COSMIC (catalogue of somatic mutations in cancer)" (2020)[URL]
59. Wang H, "A study of ALK-positive pulmonary squamous-cell carcinoma : From diagnostic methodologies to clinical efficacy", Lung Cancer, 130, pp.135~142 (2019)
60. Paik PK, "Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component", Mol Cancer Ther, 11, pp.2535~2540 (2012)
61. Dragnev KH, "ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies", Clin Lung Cancer, 15, pp.e37~e40 (2014)
62. Mamesaya N, "ALK-rearranged lung squamous cell carcinoma responding to alectinib : a case report and review of the literature", BMC Cancer, 17, pp.471~ (2017)
63. Lin G, "Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma", Ann Oncol, 31, pp.517~524 (2020)
64. Sholl LM, "The promises and challenges of tumor mutation burden as an immunotherapy biomarker : a perspective from the International Association for the Study of Lung Cancer Pathology Committee", J Thorac Oncol, 15, pp.1409~1424 (2020)
65. Sakai K, "Predicting osimertinibtreatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer(WJOG8815L)", Mol Oncol, 15, pp.126~137 (2021)

관련 논문AI추천